Sector News

Heart to heart: Novo Nordisk teams with ACC to open diabetes discussion

September 29, 2020
Life sciences

Novo Nordisk wants the heart disease community to join the diabetes conversation. As Type 2 diabetes drugs nab approvals for reduced cardiovascular risks—including Novo’s own Ozempic and Victoza—the need to communicate across specialties has grown.

To help bridge the gap, Novo Nordisk is partnering with the American College of Cardiology (ACC) in a two-year, two-pronged initiative. First, the partners will study real-world data to determine patterns and adherence to guidelines. Next, they’ll explore how to help Type 2 patients improve their heart health, working through ACC clinicians and healthcare providers, Novo Chief Medical Officer Todd Hobbs said.

The effort is a “natural progression” of Novo Nordisk’s relationships built up in the cardiovascular community over the past several years, he said.

“We’ve looked at smaller cuts of research, like with Cleveland Clinic and others, that show there’s a lot of people out there with diabetes who really should be on one of the agents, either GLP-1 or SGLT2, that are proven to lower (cardiovascular) risk, and they just aren’t,” Hobbs said.

While not an explicit part of the study, COVID-19 has magnified the risks for people with diabetes and with heart disease. The partnership was in the works before the pandemic, but the novel coronavirus has made the initiative even more timely and relevant, Hobbs said.

The first part of the work—evaluating data assessing adherence to ACC guidelines among a cohort of people with CV disease—will be done within a year. The second stage will roll out specific treatment strategies to selected regional practices and hospitals, delivered through ACC healthcare ambassadors.

In January, Novo’s next-gen GLP-1 drug Ozempic won an FDA to add CV risk-reduction language to its label, specifying the benefits for patients with Type 2 diabetes and established cardiovascular disease.

Ozempic launched in early 2018 and took off quickly, nabbing $1.64 billion in 2019 sales. It’s expected to reach $2.64 billion this year.

Novo’s newly launched Rybelsus, the oral version of Ozempic, is currently being studied as a CV preventive for patients with Type 2 diabetes. The company’s older GLP-1 diabetes med Victoza got a similar CV approval from the FDA in 2017 to add that it reduces the risk of heart attack, stroke and cardiovascular death.

While the ACC partnership doesn’t include any specific products, Hobbs said, “If we can highlight the guidelines, whether that’s ACC or ADA treatment guidelines, then our products will do well because they’re on the data.”

By: Beth Snyder Bulik

Source: Fierce Pharma

comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend